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Abstract
Background: The clinical relevance of observations of serum levels of osteoprotegerin (OPG) and receptor
activator of nuclear factor -B ligand (RANKL) in juvenile idiopathic arthritis (JIA) is not clear. To elucidate the
potential role of OPG and RANKL in JIA we determined serum levels of OPG and RANKL in patients with early JIA
compared to healthy children, and prospectively explored changes in relation to radiographic score, bone and lean
mass, severity of the disease, and treatment.
Methods: Ninety children with early oligoarticular or polyarticular JIA (ages 6-18 years; mean disease duration
19.4 months) and 90 healthy children individually matched for age, sex, race, and county of residence, were
examined at baseline and 2-year follow-up. OPG and RANKL were quantified by enzyme-immunoassay. Data were
analyzed with the use of t-tests, ANOVA, and multiple regression analyses.
Results: Serum OPG was significantly lower in patients than controls at baseline, and there was a trend towards higher
RANKL and a lower OPG/RANKL ratio. Patients with polyarthritis had significantly higher increments in RANKL from
baseline to follow-up, compared to patients with oligoarthritis. RANKL was a significant negative predictor for increments
in total body lean mass. Patients who were receiving corticosteroids (CS) or disease-modifying antirheumatic drugs
(DMARDs) at follow-up had higher OPG/RANKL ratio compared with patients who did not receive this medication.
Conclusions: The data supports that levels of OPG are lower in patients with JIA compared to healthy children,
and higher levels of RANKL is associated with more serious disease. RANKL was a significant negative predictor of
lean mass in patients with JIA. The OPG/RANKL ratio was higher in patients on DMARDs or CS treatment.
Background
Children with juvenile idiopathic arthritis (JIA) are at risk
of bone destructions and reduced bone mass. The patho-
genesis for the bone loss is complex and is influenced by
inflammation, physical inactivity, nutrition and medica-
tion. The immune and skeletal systems share a number of
regulatory molecules, and there is accumulating evidence
indicating interactions between the two systems [1].
Bone remodelling is a lifelong continuous process con-
ducted by osteoblasts, synthesizing bone matrix and its
resorption by osteoclasts. Important regulators of osteo-
clast recruitment and function are the three key mole-
cules Osteoprotegerin (OPG), Receptor Activator of
Nuclear factor -B (RANK) and its ligand (RANKL).
RANKL stimulates osteoclast production and survival
via the membrane -bound receptor RANK, [2-5] while
OPG inhibits osteoclast differentiation and activation
due to its function as a non-signalling decoy receptor
for RANKL [6]. The physiological balance between
RANKL and OPG is regulated by various calcitropic
cytokines and hormones and alterations in their ratio
are critical in the pathogenesis of bone diseases [7].
Osteoblasts and T cells are important producer cells of
RANKL. An inflammatory environment with T-cell
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activation may tilt the balance between OPG and
RANKL and increase osteoclast activation and bone
resorption.
In patients with early rheumatoid arthritis (RA), base-
line serum OPG/RANKL ratio and inflammation have
independently predicted radiographic progression of joint
damage [8]. RANKL-expressing cells and RANK-expres-
sing osteoclast precursor cells, and more limited OPG,
have been demonstrated at sites of subchondral bone
erosions [9]. In children with JIA, over expression of
RANKL has been detected in synovial fluid mononuclear
cells from joints [10]. Higher serum RANKL and lower
serum OPG/RANKL ratio has been found in two studies
of patients with JIA compared to controls [11,12], while
higher serum levels of OPG [13,14] or an increased
OPG/RANKL ratio [14] has been shown in other studies.
Publications concerning this topic in patients with JIA
are still few, the studies cross-sectional, and the clinical
relevance of the observations is not clear.
To further elucidate the potential role of OPG and
RANKL in JIA we prospectively explored serum levels
of OPG and RANKL in an observational cohort study of
children with early disease, compared to individually
matched children, and in relation to radiographic score,
bone and lean mass, disease activity, and medication.
Methods
Study participants
All Caucasian children with JIA between the ages of 6
and 18 years who were attending the Department of
Rheumatology, Oslo University Hospital, Rikshospitalet,
for the first time from May 1995 to February 1999 were
invited to participate in a two-year prospective study of
bone mass and bone turnover. Of 127 eligible patients,
108 (85%), living in 16 different counties (latitudes from
58°N to 68°N) were included. Each patient was individu-
ally matched to a healthy child with the same sex, age,
race, and county of residence who was randomly
selected from the National Population Register. The
characteristics of the total patient group, including
nutritional status, level of physical activity, markers of
bone formation and bone resorption, and bone mass,
have previously been described [15]. In the present
study we included only patients who met the JIA criteria
[16] for oligoarthritis (n = 59) or polyarthritis (n = 31)
and their controls (n = 90). Patients’ mean disease dura-
tion was 19.4 months (SD 12.3). The participants were
examined at baseline and at follow-up, a mean of 24.2
months (SD 1.4) later. The Regional Ethics Committee
for Medical Research approved the study. Written
informed consent was obtained from the parents and
from children older than 16 years.
Clinical examination
Clinical information was obtained by interviews, physical
examination and questionnaires [15,17-22].
Radiographic examination
Radiographs of the non-dominant hand and wrist were
taken for assessment of skeletal maturity of all study
subjects at baseline and follow-up [23]. Radiographs of
the patients’ knees and ankles were obtained at the time
of admission to hospital; other joints when clinically
indicated, and were scored by one of 2 trained radiolo-
gists (KD and VJ) according to a radiographic classifica-
tion system for juvenile rheumatoid arthritis: grade 0
(normal joints), grade 1 (juxtaarticular osteoporosis and/
or periarticular soft tissue swelling), grade 2 (growth
abnormality, bony erosion not present), grade 3 (growth
abnormality and marginal bony erosions), grade 4
(deformation and severe erosions), and grade 5 (gross
destruction and deformity) [24,25]. Radiographic pro-
gression was defined as an increase in the radiographic
grade during the study. An increase from grade 0 to 1
was not considered to be radiographic progression.
Laboratory measures
Venous blood samples were obtained before noon at
baseline and follow-up. Bone markers were measured in
the second void urine sample of the morning. For analy-
sis of OPG, RANKL and C-reactive protein (CRP)
serum were stored at -70°C until analyzed. OPG and
CRP (detection limit 0.16 mg/L) was quantified by
enzyme immunoassays (EIA) using commercially avail-
able matched antibodies from R&D systems (Minneapo-
lis, Minnesota) [26] and Dako cytomation (Glostrup,
Denmark), [27] respectively. RANKL was quantified by
EIA (Bender MedSystems, Vienna, Austria). Bone for-
mation was assessed by serum levels of bone-specific
alkaline phosphatase and osteocalcin, bone resorption by
serum levels of C-telopeptide of type 1 collagen and
urinary concentration of deoxypyridinoline, [28-30] and
vitamin D stores by serum concentration of 25-hydroxy-
vitamin D and the active hormonal metabolite by serum
1,25-dihydroxyvitamin D3, all samples analyzed immedi-
ately by routine laboratory methods.
Bone mass measurements
Measurements of the total body, distal radius, femoral
neck and L2-L4 of the lumbar spine were evaluated with
the same dual x-ray absorptiometry (DXA) equipment
(Lunar Expert-XL; GE Lunar, Madison, WI). All analyses
were performed by one investigator using Expert-XL
software version 1.72 and 1.91 and were read by one
investigator (GL). The bone mineral content (BMC) was
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calculated from all the regions. Fat and lean composition
of soft tissue was calculated from the total body scan.
The long-term precision of the scanner was tested daily
with minimal drift in the measurements and a coefficient
of variation (CV) of 0.5%. The in vivo precision of the
operator technique (patients and healthy subjects) was
1.6% for lumbar spine and 2.0% for femoral neck [31].
The total body BMC findings were calculated as Z-scores
in terms of the number of standard deviations (SD)
above or below the age-specific mean for healthy indivi-
duals (Z-score = [subject’s measurement - mean mea-
surement of the reference population]/SD of the
reference population). By definition, 16% of healthy chil-
dren will have a Z-score less than -1.0 SD, and 2.3% will
have a Z-score less than -2.0, but no evidence-based
guidelines exist to define osteopenia and osteoporosis in
children [32]. We defined low BMC as Z-score between
-1 SD and -2 SD and very low BMC as a Z-score > 2 SD
below the mean.
Statistical analysis
Differences between patients and matched controls for
clinical, radiographic, bone mass and laboratory mea-
sures were tested by paired samples t-test for continu-
ous variables and McNemar’s test for categorical
variables. Within the patient cohort, differences were
tested by the independent samples t-test or by one-way
analysis of variance using the Bonferroni correction for
multiple comparisons for continuous variables, and the
chi-square test for categorical variables.
Multiple regression analyses were performed to iden-
tify predictors of the 2-year changes in body lean mass,
BMC and numbers of active or mobility restricted joints.
Explanatory variables were included in the model if the
p value was less than 0.2 in unadjusted linear regression
analyses or if a variable was known to be associated
with the outcome variable [33]. Highly intercorrelated
independent variables (r > 0.7) in a multiple model were
avoided. To reduce the possibility of body size-related
Table 1 Characteristics of patients with JIA and healthy children at baseline and 2-year follow-up*
Baseline 2 year follow-up
JIA patients(n = 90) Controls(n = 90) JIA patients(n = 90) Controls(n = 90)
Characteristics
Female, n (%) 56 (62%) 56 (62%) 56 (62%) 56 (62%)
Age, mean (SD) years 10.1 (3.2) 10.1 (3.2) 12.1 (3.2) 12.2 (3.2)
Disease-onset type, n (%)
Oligoarthritis, persistent 48 (53%) - 48 (53%) -
Oligoarthritis, extended 11 (12%) - 11 (12%) -
Polyarthritis, RF negative 28 (31%) - 28 (31%) -
Polyarthritis, RF positive 3 (3%) - 3 (3%) -
Disease duration, mean (SD) months 19.4 (12.3) - 44.3 (14.2) -
No. of joints with active disease, mean (SD) † 2.2 (3.5) - 1.3 (4.2) -
No. of joints with restricted mobility, mean (SD) † 1.7 (2.6) - 1.2 (2.2) -
Radiographic score, mean (SD) ‡ 1.7 (0.6) - 1.8 (0.6) -
Radiographic erosions, n (%) § 3 (3%) - 5 (6%) -
Radiographic progression, n (%)¶ - - 9 (10%) -
Total body BMC Z-score < -1, n (%) 10 (11%) 9 (10%) 20 (22%) 12 (13%)
Disease-modifying antirheumatic drugs, current use, n (%) 48 (53%) - 37 (41%) # -
Non-steroidal anti-inflammatory drugs, current use, n (%) 68 (76%) 43 (48%)
Oral corticosteroids **
Current use, n (%) 17 (19%) - 8 (9%) -
Dosage, mean (SD) mg/day 11.2 (7.1) - 6.7 (5.9) -
Ever used, n (%) 27 (30%) - 31 (34%) -
Cumulative dose, mean (SD) mg 1234 (1328) - 1919 (2062) -
Cumulative dose, mean (SD) mg/kg of body weight 38 (42) - 52 (65) -
* Because of rounding, not all percentages total 100. JIA = juvenile idiopathic arthritis; RF = rheumatoid factor; BMC = bone mineral content.
† Sixty-nine joints were evaluated.
‡ Highest registered score from a range of 0 = best to 5 = worst.
§ Erosions = radiographic grade 3 or higher.
¶ Increase in radiographic grade from baseline to follow-up.
# Methotrexate (n = 24), hydroxychloroqine (n = 8), methotrexate plus hydroxychloroqine (n = 3), methotrexate plus sulfasalazine (n = 1) and methotrexate plus
etanercept (n = 1).
** Prednisolone. None of the patients had taken methylprednisolone.
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artefacts in the analyses of bone mass, bone area,
weight, and height were included in the multiple regres-
sion models for BMC [34]. Forward stepwise regression
methods were used.
For all analyses, p values less than or equal to 0.05
(2-tailed tests) were considered significant. The statisti-
cal analysis was performed using SPSS software version
14.0 (SPSS, Chicago, IL).
Results
Demographic and clinical data
A total of 90 JIA patients and 90 controls were included.
Clinical features at baseline and 2-year follow-up are
shown in table 1.
Serum levels in JIA patients and controls
Figure 1 shows the serum levels and changes from base-
line to 2-year follow-up in patients and controls. The
OPG level was significantly lower in the patients than in
the controls at baseline (p = 0.003). The levels of
RANKL were higher in the patients at follow-up (p =
0.073), but the findings did not reach statistical signifi-
cance. The OPG/RANKL ratio tended to be lower in
the patients than controls at baseline and follow-up (p =
0.061 and p = 0.200). The level of CRP was significantly
higher in the patients at baseline (p = 0.036). There
were no significant differences in serum levels of OPG,
RANKL, OPG/RANKL ratio or CRP between males and
females (data not shown).
Changes in serum levels, radiographic score and bone
mass
Changes in the OPG/RANKL ratio and serum levels of
CRP from baseline to 2-year follow-up, in relation to
different radiographic scores and total body BMC
Z-scores, are shown in Figure 2. No patient had higher
radiographic score than grade 3 with growth abnorm-
ality and bony erosions. The increments from baseline
to follow-up of the OPG/RANKL ratio and CRP were
significantly higher in patients with very low BMC and
patients with erosions, compared to patients with less
serious findings (p values ranged from <0.001 to
0.007). A greater increase in OPG/RANKL ratio was
also seen in patients with radiographic progression
compared to the patients without radiographic pro-
gression (difference of increase 33.7, 95%CI = 10.7,
56.7, p = 0.004).
Changes in serum levels and disease-onset type
The levels of RANKL increased significantly more from
baseline to follow-up in the polyarthritis-group than in
the oligoarthritis-group (p = 0.015), while the changes
in OPG, OPG/RANKL ratio and CRP were not signifi-
cantly different (Figure 3).
Figure 1 Serum levels in patients with JIA and controls at baseline and 2-year follow-up. A. OPG. B. RANKL. C. OPG/RANKL ratio. D. CRP. p
Values by paired samples t-test for patients vs controls. Values are the mean. Error bars represent standard error of the mean.
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Serum levels, antirheumatic and corticosteroid treatment
Figure 4 shows serum OPG, RANKL, OPG/RANKL
ratio and CRP at 2-year follow-up in relation to cur-
rent DMARD and corticosteroid treatment. The levels
of the OPG/RANKL ratio and CRP was significantly
higher in the patients who were currently treated
with DMARDs compared to the patients who were not
(p = 0.013 and p = 0.037). Analyses comparing
DMARD subgroups did not show significant differ-
ences. The serum OPG/RANKL ratio and CRP were
significantly higher as well in patients who were cur-
rent users of corticosteroids compared to those who
were not (p = 0.012 and p < 0.001).
Predective value of OPG, RANKL, OPG/RANKL ratio and
changes in lean mass, bone and affected joints
Laboratory measurements, patient and disease character-
istics, physical activity and medication assessed at base-
line were explored as independent predictors of the
2-year changes in lean mass, BMC and no. of active or
mobility restricted joints by unadjusted linear regression
analysis. Predictors chosen for the multiple regression
model of the change in total body lean mass were base-
line weight, height, bone age, weight-bearing physical
activity, serum ionized calcium, 25-hydroxyvitamin D,
parathyroid hormone, bone-specific alkaline phospha-
tase, C-telopeptide type 1, urinary deoxypyridinoline,
baseline OPG, RANKL and CRP. In the final regression
model baseline RANKL was a significant independent
negative predictor of increased lean mass at follow-up
(regression coefficient -1.5, 95% CI = -2.88,-0.12, p =
0.034) together with the independent positive predictors
weight-bearing physical activity (regression coefficient
216, 95% CI = 51, 381, p = 0.011), bone-specific alkaline
phosphatase (regression coefficient 31.7, 95% CI = 10.7,
52.6, p = 0.004) and 25-hydroxyvitamin D (regression
coefficient 38.9, 95% CI = 0.48, 77.3, p = 0.047). Serum
levels of OPG, RANKL or the OPG/RANKL ratio were
not identified as independent predictors of the changes
in BMC of total body, distal radius, femur neck or lum-
bar spine, or the changes of no. of joints with active dis-
ease or restricted mobility (data not shown).
Discussion
In the present prospective, observational cohort study of
90 JIA patients, early in the disease course, the level of
OPG was significant lower than in 90 matched healthy
children. Furthermore, during 2-years follow-up,
RANKL increased more in patients with polyarthritis
than in patients with oligoarthritis and RANKL was a
significant negative predictor of lean mass. The OPG/
RANKL ratio at follow-up was higher in patients on
DMARD or CS treatment. To our knowledge, this is the
first prospective controlled study of OPG and RANKL
in children with JIA.
The findings of lower serum levels of OPG in our JIA
patients with early disease are consistent with findings
in children with untreated juvenile dermatomyositis
[35], and so are the trends towards higher levels of
RANKL and a lower OPG/RANKL ratio. Other studies
exploring serum OPG and RANKL in JIA, differs from
Figure 2 Changes in serum levels, radiographic score and total
body BMC at 2-year follow-up in patients with JIA. Changes in
serum levels from baseline to follow-up: A. OPG/RANKL ratio. B. CRP.
The legends for radiographic score and total body BMC is valid for
panel A and B. Radiographic score grade 0 = normal joints; grade
1 = swelling/osteopoprosis; grade 2 = abnormal growth; grade 3 =
abnormal growth and erosions; BMC Z-score > -1 SD defined as
normal; BMC Z-score between -1 SD and -2 SD defined as low; BMC
Z-score < -2 SD defined as very low. p Values by one-way analysis
of variance, using the Bonferroni correction for multiple
comparisons within the groups. Values are the mean. Error bars
represent standard error of the mean.
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ours, but consist of patients with longer disease duration
[11,12,14], more severe disease [12,14] or different sub-
groups [11], complicating comparisons. A recent study
of polyarticular JIA patients showed higher serum levels
of RANKL, a lower OPG/RANKL ratio, and comparable
OPG levels compared to controls [12]. Another recent
study, with a mixture of children and adults, found simi-
lar results in oligoarticular and polyarticular subtypes of
JIA compared to controls [11]. A previous study has
shown higher serum OPG levels and a higher OPG/
RANKL ratio in oligoarticular and polyarticular JIA
patients compared to controls, in contrast to the other
studies [14]. These differences may have several expla-
nations. As mentioned, the composition, age range and
disease severity is not necessarily comparable between
the studies. Importantly, we measured free RANKL and
immunoassays measuring both OPG bound and free
RANKL may give different results. An increase in circu-
lating OPG has often been viewed as a compensatory
response [14]. However, members of the TNF ligand
superfamily often circulate at low levels with a short
half time. Thus, as seen for other soluble TNF receptors
[36], OPG may represent a reliable marker of the overall
activity of the OPG/RANK/RANKL axis as well as a
stable marker of inflammation. The correlation between
CRP and the OPG/RANKL ratio in our JIA cohort sup-
ports this.
We found that baseline RANKL was a significant and
independent negative predictor and weight-bearing phy-
sical activity a positive predictor of the gain in total body
lean mass in the JIA patients. There are few data eluci-
dating the impact of RANKL on the variation in lean
mass in children but our results are most likely related to
the chronic inflammation. In adult RA patients cachexia
Figure 3 Changes in serum levels in patients with oligoarthritis (OA) and polyartrhritis (PA). Changes from baseline to 2-year follow-up:
OPG, RANKL, OPG/RANKL ratio and CRP. p Values by independent samples t test for patients with OA vs PA. Values are the mean. Error bars
represent standard error of the mean.
Figure 4 Serum levels and DMARDs and CS at 2-year follow-up in patients with JIA. Serum levels of OPG, RANKL, OPG/RANKL ratio and
CRP. p Values by independent samples t test for current treatment with DMARD or CS vs not. Values are the mean. Error bars represent
standard error of the mean.
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with muscle wasting and fat gain is common, and the
mechanisms probably include cytokine-driven hyperme-
tabolism during active disease [37,38].
The molecular pathways and specific effects of con-
ventional DMARDs on bone and cartilage are not
clearly defined [39]. However, DMARDs may have an
effect on the osteoclast formation. In a study of cultures
of fibroblast-like synoviocytes from patients with RA,
the DMARDs methotrexate and sulfasalazine, have been
shown to decrease the ratio of RANKL/OPG in a dose-
dependent manner [40]. Another study of synovial tissue
from patients with RA, treated with DMARDs, has
shown increased OPG expression and decreased
RANKL expression [41]. Our results with an increased
OPG/RANKL ratio in DMARDs treated and corticoster-
oid treated patients are in accordance with these find-
ings. Although corticosteroids are generally not
considered conventional DMARDs there is evidence that
corticosteroids have structure-sparing effects and can
reduce the rate of erosion progression in RA [39,42].
There have been limited knowledge of the disease
course during the first years of JIA and this study was
part of a larger prospective comprehensive study [43].
Our patients were comparable to JIA patients in epide-
miologic studies [44]. They were explored early in the
disease course, the mean disease activity was low, the
numbers of patients with radiographic erosions (6%)
were low, and the numbers of patients with very low
bone mass (4%) were low. The overall low disease activ-
ity in our patients is however a limitation for the inter-
pretation of the results and the present study seems
somewhat underpowered in places with strong trends
but statistical significance not being attained. If we had
chosen a patient cohort with higher disease activity and
longer disease duration, the numbers of patients with
joint erosions and very low bone mass would more
likely have been higher. In addition, if more sensitive
imaging methods as ultrasonography and magnetic reso-
nance imaging (MRI), had been available as supplements
to conventional radiographs, we might have detected a
higher number of patients with structural damage
[45,46].
Conclusions
In summary, the JIA patients with oligo- or polyarthritis
had significant lower levels of OPG early in the disease
course compared to controls. The patients tended to
have higher levels of RANKL and a lower OPG/RANKL
ratio consistent with earlier findings. Baseline RANKL
was a significant negative predictor of total body lean
mass. To better understand bone loss and the clinical
significance of the balance between OPG and RANKL in
children with JIA more prospective data are warranted.
Inclusion of children early in the disease course and
before treatment with oral corticosteroids, DMARDs or
biologic therapy will add information to our knowledge.
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